托伐普坦片治疗肝硬化腹水低钠血症的疗效及安全性观察  

Administration of tolvaptan tablets for treating cirhosis and hyponatremia:Observation on their safety and efficacy

作　　者：唐飞[1] 吕洪敏[1] 向慧玲[1] 

机构地区：[1]天津市第三中心医院,天津300170

出　　处：《吉林医学》2014年第6期1130-1131,共2页Jilin Medical Journal

摘　　要：目的:观察托伐普坦片治疗肝硬化腹水引起的低钠血症患者的疗效及安全性。方法:40例肝硬化伴腹水形成的低钠血症患者,予以口服托伐普坦片治疗。结果:口服托伐普坦片治疗肝硬化腹水低钠血症明显优于安慰剂组(P<0.05)。结论:托伐普坦片能够明显提高肝硬化患者血清钠浓度作用,对低钠血症患者有明显疗效。没有严重并发症及不良反应,临床应用中简便且安全。Objective To investigate the efficacy and safety of tolvaptan for treating hyponatremia caused by cirrhosis.Methods The 40 subjects with cirrhosis and hyponatremia were enrolled in this study and took the tolvaptan tablets orally.Results Oral administration of tolvaptan was significantly superior to placebo for treatment hyponatremia（P 〈 0.05）.Conclusion Tolvaptan can significantly improve the role of serum sodium concentrations in patients with cirrhosis.But no severe complication and adverse reaction are found,the clinical application is also simple and safe.

关 键 词：托伐普坦 低钠血症 肝硬化 

分 类 号：R575.2[医药卫生—消化系统]